Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPd in first or second relapse multiple myeloma
2019-001169-34Phase 2Terminated
- Sponsor
- Amgen
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Amgen. Primary endpoint: Overall response rate (ORR). Started Mar 2020; status: terminated.
02
Drugs
carfilzomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-001169-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001169-34.